Laurel Habel to California
This is a "connection" page, showing publications Laurel Habel has written about California.
Connection Strength
1.710
-
Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
Score: 0.113
-
The Effect of California's Breast Density Notification Legislation on Breast Cancer Screening. J Prim Care Community Health. 2017 Apr; 8(2):55-62.
Score: 0.090
-
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. Br J Cancer. 2016 09 27; 115(7):895-900.
Score: 0.089
-
Case-control study of mammographic density and breast cancer risk using processed digital mammograms. Breast Cancer Res. 2016 05 21; 18(1):53.
Score: 0.088
-
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10; 32(20):2151-8.
Score: 0.076
-
Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy. Obstet Gynecol. 2014 Jan; 123(1):65-72.
Score: 0.074
-
Antidepressants and testicular cancer. Cancer Causes Control. 2014 Feb; 25(2):251-8.
Score: 0.074
-
Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care. 2013 Dec; 36(12):3953-60.
Score: 0.073
-
The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):82-90.
Score: 0.069
-
Mammographic density and risk of second breast cancer after ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2488-95.
Score: 0.059
-
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010 Oct 01; 28(28):4300-6.
Score: 0.059
-
Treatment of ductal carcinoma in situ among patients cared for in large integrated health plans. Am J Manag Care. 2010 May; 16(5):351-60.
Score: 0.058
-
Mothers of children diagnosed with attention-deficit/hyperactivity disorder: health conditions and medical care utilization in periods before and after birth of the child. Med Care. 2009 Jan; 47(1):105-14.
Score: 0.053
-
Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology. 2008 Dec; 135(6):1914-23, 1923.e1.
Score: 0.051
-
Glycemic status and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):628-35.
Score: 0.050
-
Physical activity and mammographic density in a cohort of midlife women. Med Sci Sports Exerc. 2008 Mar; 40(3):451-6.
Score: 0.050
-
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008 Jan; 17(1):27-36.
Score: 0.049
-
Methylphenidate use in children and risk of cancer at 18 sites: results of surveillance analyses. Pharmacoepidemiol Drug Saf. 2007 Dec; 16(12):1268-72.
Score: 0.049
-
Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr Adolesc Med. 2006 Oct; 160(10):1063-9.
Score: 0.045
-
Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat. 2006 Mar; 96(2):123-9.
Score: 0.043
-
Treatment with stimulants among youths in a large California health plan. J Child Adolesc Psychopharmacol. 2005 Feb; 15(1):62-7.
Score: 0.040
-
Barbiturates, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 Nov; 7(11):1049-50.
Score: 0.026
-
Oncologist and organizational factors associated with variation in breast cancer multigene testing. Breast Cancer Res Treat. 2017 May; 163(1):167-176.
Score: 0.023
-
Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care. 2016 05 01; 22(5):e153-60.
Score: 0.022
-
Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health. 2015 May; 105(5):938-46.
Score: 0.020
-
Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population-based cohort. PLoS Genet. 2015 Jan; 11(1):e1004930.
Score: 0.020
-
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):636-45.
Score: 0.019
-
Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat. 2014 Apr; 144(3):689-99.
Score: 0.019
-
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013 Jan; 137(1):247-60.
Score: 0.017
-
Racial and ethnic differences in adjuvant hormonal therapy use. J Womens Health (Larchmt). 2012 Sep; 21(9):950-8.
Score: 0.017
-
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 03; 379(9818):823-32.
Score: 0.016
-
Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidemiol Drug Saf. 2012 Feb; 21(2):214-25.
Score: 0.016
-
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
Score: 0.016
-
Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011 Sep; 129(2):549-56.
Score: 0.015
-
Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2479-87.
Score: 0.015
-
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs. 2009 Jul 30; 69(11):1445-57.
Score: 0.014
-
Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut. 2009 Feb; 58(2):182-8.
Score: 0.013
-
Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2008 Apr 16; 100(8):597-8; author reply 599.
Score: 0.012
-
Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2218-25.
Score: 0.012
-
Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007 Jul; 133(1):34-41; quiz 311.
Score: 0.012
-
NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007 Aug; 18(6):613-20.
Score: 0.012
-
California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health. 2006 Jun 30; 6:172.
Score: 0.011
-
The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors. J Neurooncol. 2004 May; 68(1):57-69.
Score: 0.010
-
Clinical effectiveness of rubella vaccine in a college population. Vaccine. 1985 Jun; 3(2):109-12.
Score: 0.003